https://orcid.org/0000-0003-2906-0333
References
- Gammon K . Neurodegenerative disease: brain windfall. Nature515, 299–300 (2014).
- Sink KM , HoldenKF , YaffeK. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA293(5), 596–608 (2005).
- Kuhlwilm L , Schönfeldt-LecuonaC , GahrM , ConnemannBJ , KellerF , SartoriusA. The neuroleptic malignant syndrome – a systematic case series analysis focusing on therapy regimes and outcome. Acta Psychiatr. Scand.142(3), 233–241 (2020).
- Solomon A , TurunenH , NganduTet al. Effect of the apolipoprotein E genotype on cognitive change during a multidomain lifestyle intervention: a subgroup analysis of a randomized clinical trial. JAMA Neurol.75(4), 462–470 (2018).
- Se Thoe E , FauziA , TangYQ , ChamyuangS , ChiaAYY. A review on advances of treatment modalities for Alzheimer's disease. Life Sci.276, 119129 (2021).
- Liu R , MathieuC , BertheletJ , ZhangW , DupretJ-M , RodriguesLima F. Human protein tyrosine phosphatase 1B (PTP1B): from structure to clinical inhibitor perspectives. Int. J. Mol. Sci.23(13), 7027 (2022).
- Newman EJ , GrossetDG , KennedyPG. The parkinsonism-hyperpyrexia syndrome. Neurocrit. Care10(1), 136–140 (2009).
- Castrioto A , KistnerA , KlingerHet al. Psychostimulant effect of levodopa: reversing sensitisation is possible. J. Neurol. Neurosurg. Psychiatry84, 18–22 (2013).
- Moro E , LozanoAM , PollakPet al. Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov. Disord.25, 578–586 (2010).
- Feng CW , ChenNF , ChanTF , ChenWF. Therapeutic role of protein tyrosine phosphatase 1B in Parkinson's disease via antineuroinflammation and neuroprotection in vitro and in vivo. Parkinsons Dis.2020, 8814236 (2020).
- Paganoni S , MacklinEA , HendrixSet al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N. Engl. J. Med.383(10), 919–930 (2020).
- Sun Y , LiX , BedlackR. An evaluation of the combination of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. Expert Rev. Neurother.23(1), 1–7 (2023).
- Miller TM , CudkowiczME , GengeAet al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N. Engl. J. Med.387(12), 1099–1110 (2022).
- Lee S , KimS , KangHYet al. The overexpression of TDP-43 in astrocytes causes neurodegeneration via a PTP1B-mediated inflammatory response. J. Neuroinflammation17(1), 299 (2020).
- Titcomb TJ , BaoW , DuY , LiuB , SnetselaarLG , WahlsTL. Association of multiple sclerosis with risk of mortality among a nationally representative sample of adults in the United States. Mult. Scler. J. Exp. Transl. Clin.8(2), 20552173221104009 (2022).
- McGinley MP , GoldschmidtCH , Rae-GrantAD. Diagnosis and treatment of multiple sclerosis: a review. JAMA325(8), 765–779 (2021).
- Hartung DM . Economics of multiple sclerosis disease-modifying therapies in the USA. Curr. Neurol. Neurosci. Rep.21, 28 (2021).
- Tezuka K , SuzukiM , SatoR , KawaradaS , TerasakiT , UchidaY. Activation of Annexin A2 signaling at the blood–brain barrier in a mouse model of multiple sclerosis. J. Neurochem.160(6), 662–674 (2022).
- de Boer EMJ , OrieVK , WilliamsTet al. TDP-43 proteinopathies: a new wave of neurodegenerative diseases. J. Neurol. Neurosurg. Psychiatry92, 86–95 (2021).
- Hussain H , DjurinT , RodriguezJet al. Transactivation response DNA-binding protein of 43 (TDP-43) and glial cell roles in neurological disorders. Cureus14(10), e30639 (2022).